未登录

N

Naohito Shirai

University of Shizuoka

H指数:32

被引数:3,806

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EFFECTS OF DOSING STRATEGY OF AMOXICILLIN ON ERADICATION RATES OF HELICOBACTER PYLORI WITH AMOXICILLIN-BASED TRIPLE THERAPY

GASTROENTEROLOGY

IF25.1

2017-04-010

PREAI

POTASSIUM-COMPETITIVE ACID BLOCKER VERSUS PROTON PUMP INHIBITOR AS FIRST-LINE TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

GASTROENTEROLOGY

IF25.1

2017-04-010

PREAI

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2012-08-1062

PREAI

Role of renin-angiotensin system in gastric oncogenesis

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2012-02-2127

OAAI

MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese

IF5.1

2008-08-0116

PREAI

Maintenance time of sedative effects after an intravenous infusion of diazepam: A guide for endoscopy using diazepam

WORLD JOURNAL OF GASTROENTEROLOGY

IF5.4

2008-01-014

OA

Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2007-10-0233

PREAI

Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2007-08-1590

PREAI

Role of angiotensinogen gene polymorphism on Helicobacter pylori infection-related gastric cancer risk in Japanese

IF2.9

2007-08-1127

OAAI

Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C19 genotypes and 23S rRNA genotypes of H-pylori

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2007-06-1535

OAAI

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H-pylori

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2007-01-10156

PREAI

Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer

肿瘤坏死因子 α 和interleukin-1 β 基因多态性对消化性溃疡和胃癌发生的不同影响

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2006-12-15122

PREAI

Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P4502CI9 genotype status

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2006-11-0115

PREAI

Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

IF3.4

2006-10-1148

OAAI

Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele specific primer-polymerase chain reaction method

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2006-07-0527

PREAI

Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2006-07-0137

PREAI

Hydroxylation of lansoprazole in poor metabolizers of CYP2C19

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2005-12-011

OAAI

Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2005-10-2141

PREAI

I-ApeI, a novel intron-encoded LAGLIDADG homing endonuclease from the archaeon, Aeropyrum pernix K1 (vol 33, pg e116, 2005)

NUCLEIC ACIDS RESEARCH

IF13.1

2005-09-062

OAAI

Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2005-06-1713

OAAI